Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
about
Pentoxifylline inhibits interleukin-2-induced toxicity in C57BL/6 mice but preserves antitumor efficacy.Acute pancreatitis associated with high-dose interleukin-2 immunotherapy for malignant melanomaCardiomyopathy associated with high-dose interleukin-2 therapy.Cutaneous response to recombinant interleukin 2 in human immunodeficiency virus 1-seropositive individuals.The tetravalent guanylhydrazone CNI-1493 blocks the toxic effects of interleukin-2 without diminishing antitumor efficacyAlcohol inhibits lipopolysaccharide-induced tumor necrosis factor alpha gene expression by peripheral blood mononuclear cells as measured by reverse transcriptase PCR in situ hybridization.Thyroid dysfunction from antineoplastic agents.Evidence for cytokine-inducible nitric oxide synthesis from L-arginine in patients receiving interleukin-2 therapyCTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma.Effects of nitric oxide (NO) synthesis inhibition on antitumor responses during interleukin-2 (IL-2) treatment of mice.A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part II: Immunological aspects.Thyroiditis after treatment with interleukin-2 and interferon alpha-2a.The activation of polymorphonuclear neutrophils and the complement system during immunotherapy with recombinant interleukin-2.A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part I: Clinical aspects.Passive immunization against tumor necrosis factor partially abrogates interleukin 2 toxicity.Phase I clinical trial with IL-2-transfected xenogeneic cells administered in subcutaneous metastatic tumours: clinical and immunological findings.In vitro cytokine production by normal human peripheral blood mononuclear cells as a measure of immunocompetence or the state of activation.Role of membrane-associated lymphotoxin (mLT) in the killing activity of lymphokine-activated killer (LAK) cells towards various tumour cell lines.Correlation of serum cytokine and acute phase reactant levels with alterations in weight and serum albumin in patients receiving immunotherapy with recombinant IL-2.Induction of soluble tumour necrosis factor receptors during treatment with interleukin-2.Flavone acetic acid (FAA) with recombinant interleukin-2 (TIL-2) in advanced malignant melanoma. II: Induction of nitric oxide production.In vivo cytokine production and recombinant interleukin 2 immunotherapy: an insight into the possible mechanisms underlying clinical responses.Membrane-associated lymphotoxin expression and functional analysis of lymphokine-activated killer cells derived from tumor-infiltrating lymphocytes.
P2860
Q33370145-A7631E69-E88E-4C35-97F6-B348154B4CBFQ33558311-BA9EE0E2-9AE1-457A-8D3E-77115677BC57Q33559591-9AC27AE1-131C-4AE1-A1D1-C74CF632C7B9Q33717893-AF9B6279-C752-434E-B078-33D982E09C42Q34463802-3EC677BD-AC11-4704-9768-EEB6958629C5Q35227046-C4BF943D-1942-4F5C-BDF9-1FF55BEC30C5Q35500038-E73BC543-0C2E-4092-8316-6F16E12A332AQ35599161-682E34D4-CAF6-46B3-B9D5-B1D2F5502535Q35871798-63430A27-C5AF-413B-98FE-81870D34CF34Q35938791-70B4CF74-655B-4448-A4CF-F2258DE0436FQ35976681-2994BCED-2199-42F0-8304-A639320B9DB8Q35982902-8F787831-4E9D-4194-BE2D-D82CAA59E66DQ35992936-81282184-90AE-4F9E-801A-A022BFF32EA8Q35993098-8213E1DF-CA35-4A4C-9A36-C5E67BABD593Q36356738-E0D63B11-CBCE-4714-B9B2-894273CDB40BQ36621492-875134B1-0AE4-4ACE-A1CB-41AD0389E8C6Q36928740-00549A50-59D5-44E0-AC03-968E822680D3Q41475702-8D9AA97B-A9EA-47CA-AC92-7FFAE3749B94Q41661156-F44ED80F-7CF1-4DAA-93E2-35F7007CADA4Q42057633-7BEC4F30-2D2C-410B-A9EF-7BD9F404B6D6Q42372912-92D5E674-66F9-4A83-A923-FF3832393F4BQ42388343-EA50A7B1-BCA7-4BA3-B862-AA7A03B8E937Q55094254-2055A163-9DCA-4911-8865-6F3C15A178BA
P2860
Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.
description
1988 nî lūn-bûn
@nan
1988年の論文
@ja
1988年学术文章
@wuu
1988年学术文章
@zh
1988年学术文章
@zh-cn
1988年学术文章
@zh-hans
1988年学术文章
@zh-my
1988年学术文章
@zh-sg
1988年學術文章
@yue
1988年學術文章
@zh-hant
name
Circulating cytokines in patie ...... hokine-activated killer cells.
@en
Circulating cytokines in patie ...... hokine-activated killer cells.
@nl
type
label
Circulating cytokines in patie ...... hokine-activated killer cells.
@en
Circulating cytokines in patie ...... hokine-activated killer cells.
@nl
prefLabel
Circulating cytokines in patie ...... hokine-activated killer cells.
@en
Circulating cytokines in patie ...... hokine-activated killer cells.
@nl
P2093
P1433
P1476
Circulating cytokines in patie ...... hokine-activated killer cells.
@en
P2093
Espevik TP
Palladino MA Jr
P304
P407
P577
1988-10-01T00:00:00Z